Guselkumab Mechanism of Action: How Guselkumab Works | Elicit

Guselkumab Mechanism of Action

How Guselkumab (Tremfya) Works: IL-23 pathway blockade to disrupt downstream inflammatory signaling.

Last updated: March 2026

Quick Summary

Guselkumab (Tremfya) is a human IgG1λ monoclonal antibody that binds selectively to interleukin-23 (IL-23) with high specificity and affinity. By blocking IL-23’s interaction with the cell-surface IL-23 receptor, it disrupts IL-23–mediated signaling and cytokine cascades, contributing to normalization of downstream inflammatory responses. Guselkumab exerts clinical effects in plaque psoriasis, psoriatic arthritis, ulcerative colitis, and Crohn’s disease through blockade of the IL-23 cytokine pathway.

Properties

Details
Generic Name Guselkumab
Brand Names Tremfya
Drug Class IL-23 inhibitor (monoclonal antibody)
Primary Target Interleukin-23 (IL-23) (IL23A) / IL-23 receptor (IL23R)
Approved Indications Moderate-to-severe plaque psoriasis in adults, active psoriatic arthritis (PsA) in adults
Key Effect Blocks IL-23 signaling by preventing IL-23 interaction with the IL-23 receptor, disrupting inflammatory cytokine cascades

Development History

Guselkumab was developed by Janssen Biotech as a fully human IgG1λ monoclonal antibody that selectively binds the p19 subunit of interleukin-23, neutralizing IL-23 signaling without engaging the shared p40 subunit targeted by predecessor ustekinumab. The antibody was isolated from a fully synthetic human Fab library using MorphoSys's HuCAL GOLD phage-display platform, yielding a high-affinity human sequence that sidestepped the immunogenicity risk of murine-derived scaffolds.

The pivotal program supporting first approval consisted of the Phase 3 VOYAGE 1 and VOYAGE 2 trials, both placebo- and adalimumab-controlled studies in adults with moderate-to-severe plaque psoriasis. In VOYAGE 1, 73.3% of guselkumab-treated patients achieved PASI 90 at week 16 versus 49.7% with adalimumab and 2.9% with placebo, with superiority over adalimumab sustained through week 48. VOYAGE 2 reproduced the effect, with 70.0% of patients reaching PASI 90 versus 2.4% on placebo at week 16. On the basis of these data together with the NAVIGATE switch study, the FDA approved guselkumab on July 13, 2017 under the brand name Tremfya for moderate-to-severe plaque psoriasis, administered as a 100 mg subcutaneous injection every eight weeks following starter doses at weeks 0 and 4.

Indication expansion followed a deliberate cadence across immune-mediated disease. In the Phase 3 DISCOVER-1 trial, 59% and 52% of patients on every-4-week and every-8-week guselkumab achieved ACR20 at week 24 versus 22% on placebo, supporting FDA approval of Tremfya for active psoriatic arthritis in July 2020.

Detailed Mechanism of Action

Guselkumab is a fully human IgG1λ monoclonal antibody that selectively targets the p19 subunit of interleukin-23, leaving the shared p40 subunit — and therefore IL-12 signalling — intact. Following subcutaneous injection, the antibody distributes systemically and reaches inflamed tissue. Because its Fc region is native and unmodified, guselkumab also binds with high affinity to FcγRI (CD64), a receptor constitutively expressed on IL-23-producing inflammatory myeloid cells in lesional psoriatic skin. This dual engagement — p19 blockade on the one hand and Fc-mediated anchoring to CD64+ macrophages on the other — positions the antibody directly at its primary cellular source of target cytokine.

Primary binding event and Fc-dependent IL-23 capture. At the molecular level, guselkumab occludes the p19 epitope on the IL-23 heterodimer, sterically preventing IL-23 from engaging its cognate receptor complex (IL-23R/IL-12Rβ1). Simultaneously, CD64-anchored guselkumab captures IL-23 as it is secreted from the same myeloid cell, and the entire antibody–cytokine complex is internalized into low-pH endolysosomal compartments in a time-dependent manner.

JAK–STAT3 pathway blockade. When IL-23 binds its receptor, IL-12Rβ1 associates with TYK2 and IL-23R associates with JAK2; cytokine binding triggers transphosphorylation of both kinases. Activated JAK2 and TYK2 then phosphorylate STAT3 at its canonical tyrosine residues within the IL-23R intracellular domain — Tyr-484 and Tyr-611 in the human IL-23R mediate STAT3 activation. By blocking IL-23 at its source, guselkumab prevents this entire receptor-proximal signalling cascade from initiating.

RORγt induction and Th17/Th22 amplification. STAT3 phosphorylation induced by IL-23 is the principal driver of RORγt up-regulation in CD4+ T cells; RORγt in turn transcriptionally activates IL-17A, IL-17F, and related effector cytokines. By neutralising IL-23 at the myeloid source, guselkumab dismantles this amplification circuit upstream of both the IL-17 and IL-22 arms of the effector response.

Downstream cytokine suppression and keratinocyte effects. IL-17A released by Th17 cells acts on keratinocytes to drive proliferation and the production of antimicrobial peptides, neutrophil-recruiting chemokines, and CCL20, which in turn chemoattracts additional CCR6+ IL-17-producing cells — a feed-forward inflammatory loop. Guselkumab rapidly suppresses both axes: in VOYAGE 1 pharmacodynamic analyses, guselkumab produced greater reductions in serum IL-17F and IL-22 levels than secukinumab at weeks 24 and 48.

Selective IL-23 inhibition versus dual IL-12/IL-23 blockade. Because guselkumab spares p40, IL-12-dependent Th1 differentiation, IFN-γ production, and IL-10-mediated anti-inflammatory signalling remain intact.

Clinical Relevance

Approved Indications

Key Drug Interactions (Mechanism-Based)

Contraindications

Emerging Indications

Immunology

Nephrology

Hepatology

Reproductive Health

Clinical Trials of Guselkumab

Trial Name Phase Design N Enrolled Intervention Indication Key Result Status
ASTRO 3 Randomized, Double-blind, Placebo-controlled Trial 418 Subcutaneous guselkumab (400 mg at weeks 0, 4, and 8 followed by maintenance dosing) vs placebo. Moderately to Severely Active Ulcerative Colitis At week 12, guselkumab achieved significantly higher rates of clinical remission (28% vs 6% with placebo) Ongoing
GUIDE 3b Randomized, Double-Blind, Multicentre Study 880 Guselkumab 100 mg was administered at weeks 0, 4, 12, and 20. Moderate-to-Severe Plaque Psoriasis Early intervention with guselkumab led to higher rates of complete skin clearance (PASI=0) Ongoing
QUASAR 3 Randomized, Double-Blind, Placebo-Controlled Induction and Maintenance Study 701 Intravenous guselkumab 200 mg at weeks 0, 4, and 8 Moderately to Severely Active Ulcerative Colitis At week 12 of induction, 22.6% of guselkumab patients achieved clinical remission vs. 7.9% of placebo patients Completed
GALAXI 2 3 Randomised, Double-Blind, Triple-Dummy, Treat-Through Trial 508 Intravenous guselkumab induction (200mg at weeks 0, 4, 8) Moderately to Severely Active Crohn's Disease In GALAXI-2, the coprimary endpoint was met Completed
GALAXI 3 3 Randomised, Double-Blind, Triple-Dummy, Treat-Through Trial 513 Intravenous guselkumab induction (200mg at weeks 0, 4, 8) Moderately to Severely Active Crohn's Disease In GALAXI-3, 48% of the guselkumab 200 mg group achieved the coprimary endpoint Completed
COSMOS 3b Randomised, Double-Blind, Placebo-Controlled Study 285 Guselkumab 100 mg subcutaneously at weeks 0 and 4, then every 8 weeks Active Psoriatic Arthritis At week 24, a significantly higher proportion of patients receiving guselkumab achieved an ACR20 response Completed
VOYAGE 1 3 Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Trial 837 Guselkumab 100 mg administered subcutaneously at weeks 0 and 4 Moderate-to-Severe Plaque Psoriasis At week 16, 85.1% of patients on guselkumab achieved an IGA score of 0/1 vs. 6.9% on placebo Completed
VOYAGE 2 3 Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Trial 992 Guselkumab 100 mg was given at weeks 0, 4, and every 8 weeks thereafter Moderate-to-Severe Plaque Psoriasis At week 16, significantly more patients on guselkumab achieved IGA 0/1 Completed

Guselkumab Competitive Landscape

Drug Class Representative Drug(s) Primary Molecular Target Mechanism of Action Key Efficacy Outcomes Route & Dosing Safety / Risk Profile Key Limitations
TNF inhibitors Adalimumab, Infliximab, Etanercept Tumor necrosis factor-alpha (TNF-alpha) Binds to TNF-alpha and blocks its interaction with cell surface TNF receptors ACR20 response rate of 46% in rheumatoid arthritis trials Subcutaneous injection or IV infusion Risk of serious infections and malignancies Effectiveness can decrease over time
IL-23 inhibitors (p19) Guselkumab, Risankizumab, Tildrakizumab IL-23 p19 subunit Monoclonal antibodies bind IL-23 p19 subunit and inhibit IL-23 interaction with its receptor PASI 90 at Week 16 in 70–73% vs placebo Subcutaneous or IV Common adverse reactions include upper respiratory infections Influenced by prior biologic failure
IL-17A inhibitors Secukinumab, Ixekizumab Interleukin-17A (IL-17A) Neutralizes IL-17A and reduces proinflammatory mediator release PASI 90 at Week 12 in 59% Subcutaneous injection Increased risk of mucocutaneous candida infections Observed cases of inflammatory bowel disease
IL-17A/F inhibitors Bimekizumab IL-17A and IL-17F Binds IL-17A, IL-17F, and inhibits their interaction with receptors PASI 90 at Week 16 (85% vs placebo) Subcutaneous injection Higher rates for serious adverse events Limitations on active comparator trials
IL-12/23 inhibitors (p40) Ustekinumab IL-12 and IL-23 p40 subunit Disrupts IL-12/IL-23 mediated signaling and cytokine cascades PASI 75 at Week 12 in 67% Subcutaneous or IV Risk of serious infections Theoretical risk for certain infections
JAK inhibitors Tofacitinib, Upadacitinib JAK1, JAK2, JAK3, TYK2 Blocks the JAK-STAT signaling pathway Induction achieved clinical remission in 26-33% Oral tablets or solution Increased mortality, malignancy risk Not recommended for use with biologics

Open Research Questions

What is the clinical significance of guselkumab's CD64-mediated IL-23 internalization, and does this Fc-dependent mechanism translate into superior tissue-level efficacy over other IL-23p19 inhibitors?
Understanding whether a mechanistic in vitro advantage produces better patient outcomes is critical for positioning IL-23 inhibitors against each other.

To what extent does guselkumab achieve true disease modification rather than sustained suppression, and what biomarkers predict durable remission after discontinuation? If guselkumab can reset immunological memory rather than merely suppress it, tapering or stopping therapy could become a viable strategy for a subset of patients.

How does guselkumab remodel the gut microbiome, and can microbiome signatures serve as predictive biomarkers of treatment response? Characterizing guselkumab's microbiome effects could explain heterogeneity in clinical response.

What are the determinants of primary and secondary non-response to guselkumab, and how effective is within-class IL-23 inhibitor switching after guselkumab failure? Identifying mechanisms driving inadequate response is needed to guide sequencing decisions.

How does guselkumab affect the pharmacodynamics of the IL-23/Th17 axis in axial psoriatic arthritis, and does upstream IL-23 blockade provide comparable benefit to TNF inhibition in axial disease? Whether this upstream suppression translates to structural protection in axial disease requires dedicated studies.